Phase 3 N=161 Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
Liver Cancer · Pancreatic Cancer
Primary: Postoperative Pain Experience — 78.6; 105.2 score on a scale* hour
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=675 Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Asthma
Primary: Change From Baseline in Pre-dose FEV1 at Week 12 — 0.112; 0.071 Liters — p=0.088
Phase 3 N=60 A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
Non-Infectious Uveitis of the Posterior Segment of the Eye
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye — 2.1 ETDRS Letters
Phase 1 N=24 Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
Anemia
Primary: AUC0-t — 37440.71; 34483.73; 41150.49 mUI*h/mL
Phase 2 N=20 Trametinib With GSK2141795 in BRAF Wild-type Melanoma
Melanoma
Primary: Objective Response Rate (ORR) — 5; 4 Participants
N/A N=149 The Relationship Between Vitamin D and Hepatitis B Virus Replication
Vitamin D and Hepatitis B Virus
Primary: The Dynamic Change of HBV DNA — 3.15; 3.14 IU/mL
N/A N=28 Throwers Ten Exercises On Upper Extremity Function and Explosive Power in Wheelchair Basketball and Basketball Players
Upper Extremity Injury · Sport Injury · Shoulder Pain
Primary: Measurement of Muscle Strength (Absolute Values Are Being Reported) — 3.9; 5.1; 5.7; 7.4 kg
Phase 2 N=5 S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX — 0; 3; 3 ug/kg
N/A N=602 Social Incentives To Encourage Physical Activity and Understand Predictors
Obesity
Primary: Change in Mean Daily Steps — 6162; 6975; 7237; 6814 Steps/Day
Phase 4 N=732 A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population — 0.039; 0.029…
N/A N=219 Cap Assisted Colonoscopy Enhances Quality Based Competency in Colonoscopy Among Trainees
Endoscopy, Gastrointestinal
Primary: Number of Participants That Successfully Reached the Cecum Within 30 Minutes of Insertion — 80; 67 Participants
N/A N=6 Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold
Prostatectomy
Primary: Maximum Cavernosal Nerve Stimulation Threshold — 7.5 mA
Phase 2 N=14 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Neoplasms · Triple Negative Breast Cancer · Ovarian Cancer
Primary: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs) — 1; 1 Participants
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45